#USA #San Diego #Verismo Therapeutics #SynKIR™-310 #KIR-CAR

Verismo Therapeutics Highlights Preclinical Progress of SynKIR™-310 KIR-CAR at AACR 2026

In an exciting development, Verismo Therapeutics disclosed their groundbreaking preclinical data for the SynKIR™-310 KIR-CAR therapy during the 2026 AACR Annual Meeting held in San Diego, CA. This innovative cellular therapy showcases a significant enhancement in anti-tumor activity compared to traditional single-chain CAR T therapies, especially in B cell malignancies. The findings not only point towards improved efficacy but also demonstrate a reduction in cytokine release, addressing one of the critical challenges faced in CAR T cell therapies — namely T cell exhaustion.

Focus on B Cell Malignancies

The SynKIR™-310 KIR-CAR therapy is gaining attention for its application in treating patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL). Early clinical data from the multi-site Phase 1 clinical trial (CELESTIAL-301), including ongoing studies on a 70-year-old male patient who showed a complete response after just 28 days, supports Verismo’s hopes of establishing SynKIR™-310 as a groundbreaking treatment option for stubborn B cell malignancies.

Dr. Laura A. Johnson, the Chief Scientific Officer at Verismo Therapeutics, commented on the limitations of conventional CAR T therapies. "While these therapies have significantly changed the treatment landscape for blood cancers, it is noted that nearly 50% of patients experience a relapse within six months post-treatment. Our research serves to bridge this gap by focusing on a multi-chain KIR-CAR design with an innate 'on-off' switch which aims to mitigate T cell exhaustion and ultimately enhance viability and longevity of treatment responses."

Data Insights from Preclinical Trials

The data revealed by Megan Blair, Ph.D., during the poster session emphasized that SynKIR™-310 outperformed standard approaches like tisagenlecleucel and axicabtagene ciloleucel in various in vivo models, demonstrating superior tumor-fighting capabilities. The reduced cytokine production noted hints at a potential reduction in adverse effects typically linked to cytokine storms — a common issue in CAR T therapies.

The positive signal from the early clinical assessments seems promising as the CELESTIAL-301 trial aims to continue evaluating SynKIR™-310’s effectiveness among a diverse group of patients who have previously undergone CD19 CAR T therapy. The backing from the Institute for Follicular Lymphoma Innovation (IFLI) underscores the importance of this therapy as IFLI is investing significant resources to promote its development.

The Road Ahead

As Verismo Therapeutics advances the SynKIR™-310 KIR-CAR towards broader trials, the clinical community is closely watching the emerging data for indications that this innovative therapy can address the growing concerns surrounding T cell exhaustion and enhance overall treatment durability. The promise seen with SynKIR™-310 presents hope to many patients grappling with aggressive B cell malignancies, particularly for those who have had limited options thus far.

Through continuous innovation, Verismo remains committed to transforming the future of cancer treatment, as they leverage their multi-chain KIR-CAR technology in developing robust solutions for complex malignancies.

For further updates on the CELESTIAL-301 trial and SynKIR™-310 KIR-CAR advancements, visit their official website at verismotherapeutics.com.